MORGANTOWN, W.Va., April 1, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. ("Protea") announced today that Steve Turner, Protea's CEO, will present at the Needham & Company 13th Annual Healthcare Conference on Tuesday, April 8th, 2014 at 11:20 AM, at the Westin Grand Central Hotel in New York City. Mr. Turner will provide a corporate update and will be available for one-on-one meetings with conference attendees.
"We are pleased to be invited back to present at the Needham Healthcare Conference," stated Steve Turner, CEO. He added, "This past year Protea experienced increased sales of its product and services, and made significant investments in research and commercial development."
In 2013 Protea reported sales of 5 LAESI (Laser Ablation Electrospray Ionization) instruments in 2013. In addition, the Company launched its direct molecular imaging services centered around its proprietary LAESI mass spectrometry imaging technology that is led by what it believes is an expert scientific staff and features state of the art instrumentation. Protea's customers now include pharmaceutical, biotechnology, agricultural, chemical and materials companies as well as academic research institutions.
A live webcast of the presentation can be accessed online at www.proteabio.com/investors and will be available for 90 days.
More information about the upcoming conference can be found at: http://www.needhamco.com/Default/InstitutionalSalesAndTrading/Conferences.aspx
About Protea Biosciences Group, Inc.
Protea is a commercial stage molecular information company, leading in the field of mass spectrometry molecular imaging - the identification and localization of the molecular products of living cells, that is foundational science for all pharmaceutical, medical, and life science research.
This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
CONTACT: For more Information: Protea Biosciences, Inc., 955 Hartman Run Road, Morgantown, WV 26507 Phone: 304.292.2226 Fax: 304.292.7101 email@example.com www.proteabio.com www.proteabio.com/investors Investor Contact: Jeff Ramson, ProActive Capital Group 646-863-6341 firstname.lastname@example.org
Source:Protea Biosciences, Inc.